Quest for the right Drug

|
עמוד הבית / אינסולטרד ויאל / מידע מעלון לרופא

אינסולטרד ויאל INSULATARD VIAL (INSULIN (HUMAN))

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תת-עורי : S.C

צורת מינון:

תרחיף להזרקה : SUSPENSION FOR INJECTION

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1    Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, intermediate-acting, insulin (human). ATC code: A10AC01.

Mechanism of action and pharmacodynamic effects

The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Insulatard is a human insulin with gradual onset and long duration of action.
Onset of action is within 1½ hours, reaches a maximum effect within 4–12 hours and the entire duration of action is approximately 24 hours.

Pharmacokinetic Properties

5.2    Pharmacokinetic properties

Insulin in the blood stream has a half-life of a few minutes. Consequently, the time-action profile of an insulin preparation is determined solely by its absorption characteristics.

This process is influenced by several factors (e.g. insulin dose, injection route and site, thickness of subcutaneous fat, type of diabetes). The pharmacokinetics of insulin medicinal products are therefore affected by significant intra- and inter-individual variation.

Absorption

The maximum plasma concentration of the insulin is reached within 2–18 hours after subcutaneous administration.

Distribution

No profound binding to plasma proteins, except circulating insulin antibodies (if present) has been observed.

Metabolism

Human insulin is reported to be degraded by insulin protease or insulin-degrading enzymes and possibly protein disulfide isomerase. A number of cleavage (hydrolysis) sites on the human insulin molecule have been proposed; none of the metabolites formed following the cleavage are active.

Elimination

The terminal half-life is determined by the rate of absorption from the subcutaneous tissue. The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of insulin from plasma (insulin in the blood stream has a t½ of a few minutes). Trials have indicated a t½ of about 5–10 hours.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

NOVO NORDISK LTD., ISRAEL

רישום

049 88 26013 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

18.01.21 - עלון לרופא

עלון מידע לצרכן

20.07.21 - עלון לצרכן אנגלית 20.07.21 - עלון לצרכן עברית 20.07.21 - עלון לצרכן ערבית 18.01.21 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אינסולטרד ויאל

קישורים נוספים

RxList WebMD Drugs.com